E Fund Management Co. Ltd. Sells 342 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

E Fund Management Co. Ltd. decreased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,295 shares of the biopharmaceutical company’s stock after selling 342 shares during the period. E Fund Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $2,893,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in ALNY. Huntington National Bank raised its position in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares during the period. Hollencrest Capital Management bought a new stake in Alnylam Pharmaceuticals in the third quarter worth about $29,000. R Squared Ltd bought a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $33,000. Washington Trust Advisors Inc. bought a new stake in Alnylam Pharmaceuticals in the third quarter worth about $42,000. Finally, True Wealth Design LLC raised its position in Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 153 shares during the period. Institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 9th. Needham & Company LLC reiterated a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Sanford C. Bernstein reduced their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Chardan Capital reiterated a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $296.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $304.26.

Alnylam Pharmaceuticals Trading Down 0.4 %

Shares of ALNY stock opened at $248.13 on Friday. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The business has a 50-day moving average price of $254.46 and a two-hundred day moving average price of $261.81. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The firm has a market cap of $32.12 billion, a P/E ratio of -114.35 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Jeffrey V. Poulton sold 967 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the sale, the chief financial officer now owns 32,786 shares of the company’s stock, valued at approximately $8,366,003.62. The trade was a 2.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CMO Pushkal Garg sold 1,752 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $251.00, for a total value of $439,752.00. Following the completion of the sale, the chief marketing officer now directly owns 15,705 shares of the company’s stock, valued at approximately $3,941,955. This trade represents a 10.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 72,986 shares of company stock valued at $20,397,849 over the last 90 days. Insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.